The report evaluated 15 of the largest commercial formularies for prescription drugs in the U.S. to determine how they matched fair access criteria developed by ICER.

A new report attempts to pierce the veil of drug pricing and insurance coverage, an area that is marked by a lack of industry data and a surfeit of horror stories from consumers. Overall, the report noted the limitations of its conclusions but found that most payers seemed to be providing fair access for the drugs in the analysis, based on the available data.

The first annual “Barriers to Fair Access” report was released by the Institute for Clinical and Economic Review (ICER), a nonprofit research group that explores the effectiveness and value of prescription drug pricing.

Complete your profile to continue reading and get FREE access to, part of your ALM digital membership.

Your access to unlimited content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Critical information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events.
  • Access to other award-winning ALM websites including and

Already have an account?


Join BenefitsPRO

Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join now!

  • Unlimited access to - your roadmap to thriving in a disrupted environment
  • Access to other award-winning ALM websites including and
  • Exclusive discounts on and ALM events.

Already have an account? Sign In Now
Join BenefitsPRO

Copyright © 2023 ALM Global, LLC. All Rights Reserved.